Search Results
Sep 01, 2026, 08:15 ET Chesapeake Utilities Corporation Announces Sale of 49% Ownership Interest in Florida Energy Pathway Project
DOVER, Del., Sept. 1, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK), through its indirect subsidiary Peninsula Pipeline Holdings, LLC ("Peninsula"), today announced it sold a minority interest in Florida Energy Pathway
More news about: Chesapeake Utilities Corporation
Aug 06, 2026, 16:30 ET CHESAPEAKE UTILITIES CORPORATION REPORTS SECOND QUARTER 2026 RESULTS
DOVER, Del., Aug. 6, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK) ("Chesapeake Utilities" or the "Company") today announced financial results for the three and six months ended June 30, 2026.
More news about: Chesapeake Utilities Corporation
Aug 06, 2026, 14:56 ET Chesapeake Utilities Corporation Announces Quarterly Dividend
Aug. 6, 2026 /PRNewswire/ -- At their meeting held yesterday, the Board of Directors of Chesapeake Utilities Corporation (NYSE: CPK) declared a quarterly cash dividend of $0.735 per share on the Company's common stock. The $0.735 per share dividend will be paid on October 5, 2026,
More news about: Chesapeake Utilities Corporation
Aug 06, 2026, 07:30 ET Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business Update
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio, Inc.
Aug 04, 2026, 08:00 ET Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual Congresses
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Non-Segmental Vitiligo
rials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients
More news about: AbbVie
Jul 29, 2026, 03:00 ET AbbVie Announces European Commission Approval of RINVOQ® (upadacitinib) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients
More news about: AbbVie
Jul 21, 2026, 16:30 ET Chesapeake Utilities to Host its Second Quarter 2026 Earnings Conference Call and Webcast on August 7, 2026
DOVER, Del., July 21, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK) will host a conference call on Friday, August 7, 2026 at 8:30 a.m. ET to discuss the Company's financial results for the second quarter ended June 30,
More news about: Chesapeake Utilities Corporation
Jul 13, 2026, 08:04 ET Chesapeake Utilities Corporation Announces Florida Energy Pathway Project
Chesapeake Utilities Corporation (NYSE: CPK) (the "Company" or "Chesapeake Utilities") and its subsidiary, Peninsula Pipeline Company ("PPC"), today announced the Florida Energy Pathway ("FEP"),
More news about: Chesapeake Utilities Corporation
Jun 29, 2026, 08:00 ET Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients
More news about: AbbVie
Jun 29, 2026, 03:10 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Severe Alopecia Areata
trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients
More news about: AbbVie
Jun 29, 2026, 03:00 ET AbbVie Receives Positive CHMP Opinion for Upadacitinib (RINVOQ®) for the Treatment of Adults and Adolescents with Non-segmental Vitiligo
trials (≥2% of patients in at least one of the indications) with RINVOQ 15 mg were upper respiratory tract infections, blood creatine phosphokinase (CPK) increased, ALT increased, bronchitis, nausea, neutropenia, cough, AST increased, and hypercholesterolemia. Overall, the safety profile observed in patients
More news about: AbbVie
Jun 12, 2026, 08:00 ET Jazz Pharmaceuticals Provides Update on Zepzelca® (lurbinectedin) Phase 3 LAGOON Trial in Second-Line Small Cell Lung Cancer
extravasation.Rhabdomyolysis Rhabdomyolysis has been reported in patients treated with ZEPZELCA.Monitor creatine phosphokinase (CPK) prior to initiating ZEPZELCA and periodically during treatment as clinically indicated. Withhold or reduce the dose based on severity. ZEPZELCA
More news about: Jazz Pharmaceuticals plc
May 27, 2026, 08:00 ET Nuvation Bio to Present New Quality-of-Life Data for IBTROZI® (Taletrectinib) in Patients with ROS1-Positive Non-Small Cell Lung Cancer at ASCO 2026 Annual Meeting
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
May 15, 2026, 16:29 ET Chesapeake Utilities Corporation to Participate in the 2026 AGA Financial Forum
DOVER, Del., May 15, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK or the "Company") today announced that members of its senior leadership team will participate in the American Gas Association (AGA) Financial Forum,
More news about: Chesapeake Utilities Corporation
May 13, 2026, 16:05 ET Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer
patients. Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months). Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
May 06, 2026, 16:15 ET CHESAPEAKE UTILITIES CORPORATION REPORTS FIRST QUARTER 2026 RESULTS
DOVER, Del., May 6, 2026 /PRNewswire/ -- Chesapeake Utilities Corporation (NYSE: CPK) ("Chesapeake Utilities" or the "Company") today announced financial results for the three months ended March 31, 2026.
More news about: Chesapeake Utilities Corporation
May 06, 2026, 12:16 ET Chesapeake Utilities Corporation Raises Dividend by 7.3 Percent
May 6, 2026 /PRNewswire/ -- At their meeting held today, the Board of Directors of Chesapeake Utilities Corporation (NYSE: CPK) voted to increase the quarterly cash dividend on the Company's common stock from $0.685 per share to $0.735 per share. The Board's action raises the
More news about: Chesapeake Utilities Corporation
May 06, 2026, 08:00 ET Nuvation Bio Announces FDA Acceptance of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in Advanced ROS1-Positive Non-Small Cell Lung Cancer
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
May 05, 2026, 08:55 ET NYSE Content Update: DDN's Kevin Delane Sets Sights on Scaling AI Leadership
activity, and today's opening bell, download the NYSE TV app at tv.nyse.comOpening BellChesapeake Utilities Corporation (NYSE: CPK) celebrates Beth Cooper, Chief Financial Officer, as she retires following 36 years of dedicated service, including 18 years as CFOClosing
More news about: New York Stock Exchange
May 04, 2026, 16:10 ET Nuvation Bio Reports First Quarter 2026 Financial Results and Provides Business Update
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
Apr 27, 2026, 08:00 ET Nuvation Bio Announces National Comprehensive Cancer Network® Adds Taletrectinib (IBTROZI®) as Recommended Option to Clinical Practice Guidelines in Oncology for Central Nervous System Cancers
patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9%
More news about: Nuvation Bio Inc.
Apr 27, 2026, 07:55 ET Xcovery Partners with EVERSANA to Commercialize Lung Cancer Drug Ensacove in the U.S.
disturbances.Increased Creatine Phosphokinase (CPK) occurred in 43% of patients who had CPK laboratory data available, with Grade 3 in 1.5% and 0.5% Grade 4. Advise patients to report any unexplained muscle pain, tenderness, or weakness. Monitor CPK periodically during treatment.Hyperuricemia
More news about: EVERSANA